Paradoxical Association of Enhanced Cholesterol Efflux with Increased Incident Cardiovascular Risks

Overview

Journal Arterioscler Thromb Vasc Biol

Date 2013 Mar 23

PMID 23520163

Citations 141

Authors

Xin-Min Li

Wai Hong Wilson Tang

Marian K Mosior

Ying Huang

Yuping Wu

William Matter

Vivian Gao

David Schmitt

Joseph A DiDonato

Edward A Fisher

Jonathan D Smith

Stanley L Hazen

Affiliations

Soon will be listed here.

Abstract

Objective: Diminished cholesterol efflux activity of apolipoprotein B (apoB)-depleted serum is associated with prevalent coronary artery disease, but its prognostic value for incident cardiovascular events is unclear. We investigated the relationship of cholesterol efflux activity with both prevalent coronary artery disease and incident development of major adverse cardiovascular events (death, myocardial infarction, or stroke).

Approach And Results: Cholesterol efflux activity from free cholesterol-enriched macrophages was measured in 2 case-control cohorts: (1) an angiographic cohort (n=1150) comprising stable subjects undergoing elective diagnostic coronary angiography and (2) an outpatient cohort (n=577). Analysis of media from cholesterol efflux assays revealed that the high-density lipoprotein fraction (1.063<d<1.21) contained only a minority (≈ 40%) of [(14)C]cholesterol released, with the majority found within the lipoprotein particle-depleted fraction, where ≈ 60% was recovered after apolipoprotein A1 immunoprecipitation. Albumin immunoprecipitation recovered another ≈ 30% of radiolabeled cholesterol within this fraction. Enhanced cholesterol efflux activity from ATP-binding cassette transporter A1-stimulated macrophages was associated with reduced risk of prevalent coronary artery disease in unadjusted models within both cohorts; however, the inverse risk relationship remained significant after adjustment for traditional coronary artery disease risk factors only within the outpatient cohort. Surprisingly, higher cholesterol efflux activity was associated with increase in prospective (3 years) risk of myocardial infarction/stroke (adjusted hazard ratio, 2.19; 95% confidence interval, 1.02-4.74) and major adverse cardiovascular events (adjusted hazard ratio, 1.85; 95% confidence interval, 1.11-3.06).

Conclusions: Heightened cholesterol efflux to apoB-depleted serum was paradoxically associated with increased prospective risk for myocardial infarction, stroke, and death. The majority of released radiolabeled cholesterol from macrophages in cholesterol efflux activity assays does not reside within a high-density lipoprotein particle.

Citing Articles

Involvement of Expression of miR33-5p and ABCA1 in Human Peripheral Blood Mononuclear Cells in Coronary Artery Disease.

Torres-Paz Y, Gamboa R, Fuentevilla-Alvarez G, Cardoso-Saldana G, Martinez-Alvarado R, Soto M Int J Mol Sci. 2024; 25(16).

PMID: 39201292 PMC: 11354752. DOI: 10.3390/ijms25168605.

High-Density Lipoprotein Subclasses and Their Role in the Prevention and Treatment of Cardiovascular Disease: A Narrative Review.

Chen Q, Abudukeremu A, Li K, Zheng M, Li H, Huang T Int J Mol Sci. 2024; 25(14).

PMID: 39063097 PMC: 11277419. DOI: 10.3390/ijms25147856.

The Gut Microbiome Affects Atherosclerosis by Regulating Reverse Cholesterol Transport.

Jiang Y, Pang S, Liu X, Wang L, Liu Y J Cardiovasc Transl Res. 2024; 17(3):624-637.

PMID: 38231373 DOI: 10.1007/s12265-024-10480-3.

Proteomic Determinants of Variation in Cholesterol Efflux: Observations from the Dallas Heart Study.

Gangwar A, Deodhar S, Saldanha S, Melander O, Abbasi F, Pearce R Int J Mol Sci. 2023; 24(21).

PMID: 37958510 PMC: 10648649. DOI: 10.3390/ijms242115526.

Inverse Correlation of Cholesterol Efflux Capacity with Peripheral Plaque Volume Measured by 3D Ultrasound.

Noflatscher M, Hunjadi M, Schreinlechner M, Sommer P, Lener D, Theurl M Biomedicines. 2023; 11(7).

PMID: 37509557 PMC: 10376979. DOI: 10.3390/biomedicines11071918.

References

Khera A, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke M, Jafri K . Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011; 364(2):127-35. PMC: 3030449. DOI: 10.1056/NEJMoa1001689. View

Tang W, Wang Z, Cho L, Brennan D, Hazen S . Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. J Am Coll Cardiol. 2009; 53(22):2061-7. PMC: 2755213. DOI: 10.1016/j.jacc.2009.02.036. View

Rosenson R, Brewer Jr H, Davidson W, Fayad Z, Fuster V, Goldstein J . Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012; 125(15):1905-19. PMC: 4159082. DOI: 10.1161/CIRCULATIONAHA.111.066589. View

Favari E, Lee M, Calabresi L, Franceschini G, Zimetti F, Bernini F . Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein. J Biol Chem. 2004; 279(11):9930-6. DOI: 10.1074/jbc.M312476200. View

Ha J, Ha C, Chao J, Petersen C, Theriault A, Bhagavan N . Human serum albumin and its structural variants mediate cholesterol efflux from cultured endothelial cells. Biochim Biophys Acta. 2003; 1640(2-3):119-28. DOI: 10.1016/s0167-4889(03)00027-2. View

de Vries R, Groen A, Dullaart R . Cholesterol efflux capacity and atherosclerosis. N Engl J Med. 2011; 364(15):1473-4. DOI: 10.1056/NEJMc1101853. View

Voight B, Peloso G, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen M . Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012; 380(9841):572-80. PMC: 3419820. DOI: 10.1016/S0140-6736(12)60312-2. View

Chirinos J, Zambrano J, Chakko S, Schob A, Goldberg R, Perez G . Ability of serum to decrease cellular acylCoA:cholesterol acyl transferase activity predicts cardiovascular outcomes. Circulation. 2005; 112(16):2446-53. DOI: 10.1161/CIRCULATIONAHA.104.521815. View

Wang Z, Tang W, Cho L, Brennan D, Hazen S . Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition. Arterioscler Thromb Vasc Biol. 2009; 29(9):1383-91. PMC: 2755199. DOI: 10.1161/ATVBAHA.109.185645. View

10.

de Vries R, Groen A, Perton F, Dallinga-Thie G, van Wijland M, Dikkeschei L . Increased cholesterol efflux from cultured fibroblasts to plasma from hypertriglyceridemic type 2 diabetic patients: roles of pre beta-HDL, phospholipid transfer protein and cholesterol esterification. Atherosclerosis. 2007; 196(2):733-41. DOI: 10.1016/j.atherosclerosis.2006.12.027. View

11.

Rader D, Tall A . The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis?. Nat Med. 2012; 18(9):1344-6. DOI: 10.1038/nm.2937. View

12.

Nissen S, Tardif J, Nicholls S, Revkin J, Shear C, Duggan W . Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007; 356(13):1304-16. DOI: 10.1056/NEJMoa070635. View

13.

Travis A, Kopf G . The role of cholesterol efflux in regulating the fertilization potential of mammalian spermatozoa. J Clin Invest. 2002; 110(6):731-6. PMC: 151136. DOI: 10.1172/JCI16392. View

14.

Kane J, Malloy M . Prebeta-1 HDL and coronary heart disease. Curr Opin Lipidol. 2012; 23(4):367-71. DOI: 10.1097/MOL.0b013e328353eef1. View

15.

Guey L, Pullinger C, Ishida B, OConnor P, Zellner C, Francone O . Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease. Am J Cardiol. 2011; 108(3):360-6. DOI: 10.1016/j.amjcard.2011.03.054. View

16.

Mulya A, Lee J, Gebre A, Thomas M, Colvin P, Parks J . Minimal lipidation of pre-beta HDL by ABCA1 results in reduced ability to interact with ABCA1. Arterioscler Thromb Vasc Biol. 2007; 27(8):1828-36. DOI: 10.1161/ATVBAHA.107.142455. View

17.

Nestel P, Hoang A, Sviridov D, Straznicky N . Cholesterol efflux from macrophages is influenced differentially by plasmas from overweight insulin-sensitive and -resistant subjects. Int J Obes (Lond). 2011; 36(3):407-13. DOI: 10.1038/ijo.2011.170. View

18.

Nissen S, Tuzcu E, Brewer H, Sipahi I, Nicholls S, Ganz P . Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med. 2006; 354(12):1253-63. DOI: 10.1056/NEJMoa054699. View

19.

Hung K, Berisha S, Ritchey B, Santore J, Smith J . Red blood cells play a role in reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2012; 32(6):1460-5. PMC: 3360517. DOI: 10.1161/ATVBAHA.112.248971. View

20.

Brown M, Goldstein J . The receptor model for transport of cholesterol in plasma. Ann N Y Acad Sci. 1985; 454:178-82. DOI: 10.1111/j.1749-6632.1985.tb11856.x. View